Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that members of management will be participating in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City.

To register for one-on-one meetings with management in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com .

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com

Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

RAD:AU
Radiopharm Theranostics

Radiopharm Theranostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Radiopharm Theranostics

Radiopharm Theranostics


Keep reading...Show less

Developing innovative radiopharmaceuticals for a highly underserved oncology sector

Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis 

Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis 

Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins

Underscores Radiopharm's commitment to developing transformative oncology radiopharmaceuticals

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to stand for election to the Company's Board of Directors at its 2025 Annual General Meeting of shareholders to be held on May 28, 2025.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×